SEC Form 4 · accession 0001144204-18-040247
Yarrow Bioscience, Inc. · YARW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jul 24, 2018
Accepted (ET)
Jul 26, 2018 · 7:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001566044
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 24, 2018 | S | 487,500 | $7.65 | D | 1,907,568 | I | By Presidio Partners 2007, L.P. |
| Common StockF2 | Jul 24, 2018 | S | 12,500 | $7.65 | D | 48,910 | I | By Presidio Partners 2007 (Parallel), L.P. |
| Common StockF3 | holding | — | — | — | 152,062 | I | By David J. Collier |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Securities directly held by Presidio Partners 2007, L.P. ("Presidio Partners"). Presidio Partners 2007 GP, L.P. ("Presidio GP") is the sole general partner of Presidio Partners. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio GP, and may be deemed to have voting control and investment power over the securities held by Presidio Partners, but disclaim beneficial ownership of the securities held by Presidio Partners, except to the extent of their pecuniary interest therein.
- F2Securities directly held by Presidio Partners 2007 (Parallel), L.P. ("Presidio Parallel"). Presidio GP is the sole general partner of Presidio Parallel. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio Parallel, and may be deemed to have voting control and investment power over the securities held by Presidio Parallel, but disclaim beneficial ownership of the securities held by Presidio Parallel, except to the extent of their pecuniary interest therein.
- F3Securities directly held by David J. Collier, M.D.